The loss of PC2 elevates Wnt7a and Wnt9a expression, leading to β-catenin activation and β-catenin–mediated transcription activation. This eventually increases renal epithelial cell proliferation and promotes cystogenesis. Treatment with XAV939 or LGK974 suppresses β-catenin activity and decreases the expression of downstream Wnt signaling factors, such as Axin2, c-Myc, and cyclin D1, thereby arresting aberrant cell proliferation and inhibiting cystogenesis.